Nifty
Sensex
:
:
17274.30
58065.47
386.95 (2.29%)
1276.66 (2.25%)

Pharmaceuticals & Drugs - Global

Rating :
33/99

BSE: 532531 | NSE: STAR

338.15
03-Oct-2022
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 327.95
  • 344.50
  • 327.00
  • 332.15
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  705667
  •  2395.24
  •  608.95
  •  263.35

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 3,047.29
  • N/A
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 5,651.90
  • N/A
  • 1.34

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 30.37%
  • 0.00%
  • 22.29%
  • FII
  • DII
  • Others
  • 21.21%
  • 15.12%
  • 11.01%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -1.70
  • 0.99

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -11.38
  • -17.82

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -27.37
  • 14.42

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.41
  • 9.53
  • 9.58

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.84
  • 1.83
  • 1.84

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 18.45
  • 16.03
  • 17.62

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 22
Jun 21
Var%
Mar 22
Mar 21
Var%
Dec 21
Dec 20
Var%
Sep 21
Sep 20
Var%
Net Sales
940.07
688.37
36.56%
866.02
908.49
-4.67%
794.39
832.02
-4.52%
721.47
793.56
-9.08%
Expenses
888.88
743.72
19.52%
823.85
751.26
9.66%
792.86
672.62
17.88%
735.04
636.35
15.51%
EBITDA
51.19
-55.35
-
42.16
157.24
-73.19%
1.53
159.41
-99.04%
-13.57
157.21
-
EBIDTM
5.45%
-8.04%
4.87%
17.31%
0.19%
19.16%
-1.88%
19.81%
Other Income
22.51
18.65
20.70%
86.06
13.05
559.46%
10.19
14.40
-29.24%
22.21
17.75
25.13%
Interest
54.54
41.45
31.58%
49.48
41.61
18.91%
42.25
34.68
21.83%
43.55
36.87
18.12%
Depreciation
60.40
54.88
10.06%
60.68
51.86
17.01%
60.90
52.51
15.98%
56.56
52.79
7.14%
PBT
-107.01
-224.58
-
-58.88
75.89
-
-106.86
72.85
-
-151.37
98.44
-
Tax
-28.07
-35.54
-
-131.48
11.49
-
-4.48
10.77
-
-6.76
6.10
-
PAT
-78.94
-189.04
-
72.60
64.40
12.73%
-102.38
62.07
-
-144.61
92.34
-
PATM
-8.40%
-27.46%
8.38%
7.09%
-12.89%
7.46%
-20.04%
11.64%
EPS
-15.13
-22.87
-
3.25
5.14
-36.77%
-13.55
4.22
-
-18.11
9.03
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Net Sales
3,321.95
3,070.25
3,315.87
2,981.12
3,108.33
3,344.37
3,826.22
2,862.19
1,195.85
1,340.96
961.76
Net Sales Growth
3.09%
-7.41%
11.23%
-4.09%
-7.06%
-12.59%
33.68%
139.34%
-10.82%
39.43%
 
Cost Of Goods Sold
1,624.84
1,502.32
1,332.79
1,122.48
1,085.20
1,378.84
1,281.17
1,502.29
560.49
714.67
491.82
Gross Profit
1,697.11
1,567.93
1,983.08
1,858.64
2,023.14
1,965.53
2,545.05
1,359.90
635.37
626.30
469.94
GP Margin
51.09%
51.07%
59.81%
62.35%
65.09%
58.77%
66.52%
47.51%
53.13%
46.71%
48.86%
Total Expenditure
3,240.63
3,090.36
2,689.06
2,470.90
2,811.65
3,108.66
3,309.30
2,481.62
967.00
1,117.54
861.18
Power & Fuel Cost
-
71.54
64.58
64.49
54.39
51.33
33.87
77.18
16.02
18.56
12.84
% Of Sales
-
2.33%
1.95%
2.16%
1.75%
1.53%
0.89%
2.70%
1.34%
1.38%
1.34%
Employee Cost
-
646.91
550.15
442.56
329.44
434.05
419.16
357.69
172.06
157.18
120.30
% Of Sales
-
21.07%
16.59%
14.85%
10.60%
12.98%
10.95%
12.50%
14.39%
11.72%
12.51%
Manufacturing Exp.
-
255.52
237.94
210.79
150.98
115.97
137.47
119.23
41.37
35.76
44.43
% Of Sales
-
8.32%
7.18%
7.07%
4.86%
3.47%
3.59%
4.17%
3.46%
2.67%
4.62%
General & Admin Exp.
-
223.67
191.73
191.89
150.10
194.38
172.63
198.71
86.25
66.37
58.16
% Of Sales
-
7.29%
5.78%
6.44%
4.83%
5.81%
4.51%
6.94%
7.21%
4.95%
6.05%
Selling & Distn. Exp.
-
331.30
223.22
137.07
111.22
208.85
161.12
129.57
61.37
66.67
39.94
% Of Sales
-
10.79%
6.73%
4.60%
3.58%
6.24%
4.21%
4.53%
5.13%
4.97%
4.15%
Miscellaneous Exp.
-
59.10
88.65
301.61
930.33
725.25
1,103.88
96.95
29.44
58.33
39.94
% Of Sales
-
1.92%
2.67%
10.12%
29.93%
21.69%
28.85%
3.39%
2.46%
4.35%
9.74%
EBITDA
81.31
-20.11
626.81
510.22
296.68
235.71
516.92
380.57
228.85
223.42
100.58
EBITDA Margin
2.45%
-0.65%
18.90%
17.12%
9.54%
7.05%
13.51%
13.30%
19.14%
16.66%
10.46%
Other Income
140.97
131.99
59.44
66.70
322.90
920.64
398.08
102.37
38.57
60.23
34.20
Interest
189.82
176.74
150.06
155.72
79.29
196.24
183.10
168.17
47.44
108.88
79.45
Depreciation
238.54
233.01
206.29
187.79
171.85
193.93
198.69
131.25
64.03
56.48
30.86
PBT
-424.12
-297.88
329.90
233.42
368.44
766.17
533.20
183.50
155.95
118.30
24.48
Tax
-170.79
-178.26
31.65
17.91
14.49
21.41
51.19
42.45
147.60
40.86
11.15
Tax Rate
40.27%
32.91%
8.48%
11.50%
3.71%
2.96%
10.30%
29.87%
99.35%
44.53%
1.54%
PAT
-253.33
-349.40
352.32
143.62
370.31
681.31
399.38
113.21
1.57
50.89
712.39
PAT before Minority Interest
-243.22
-363.44
341.61
137.82
375.57
701.18
445.58
99.68
0.98
50.89
713.44
Minority Interest
10.11
14.04
10.71
5.80
-5.26
-19.87
-46.20
13.53
0.59
0.00
-1.05
PAT Margin
-7.63%
-11.38%
10.63%
4.82%
11.91%
20.37%
10.44%
3.96%
0.13%
3.80%
74.07%
PAT Growth
-950.96%
-
145.31%
-61.22%
-45.65%
70.59%
252.78%
7,110.83%
-96.91%
-92.86%
 
EPS
-28.21
-38.91
39.23
15.99
41.24
75.87
44.47
12.61
0.17
5.67
79.33

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Shareholder's Funds
2,359.23
2,776.66
2,527.42
2,648.70
2,463.66
2,748.82
2,657.87
1,144.92
1,006.83
2,026.24
Share Capital
89.79
89.68
89.56
89.55
89.50
89.42
89.35
59.62
59.57
58.80
Total Reserves
2,266.99
2,682.26
2,432.13
2,551.59
2,365.10
2,650.55
2,562.75
1,084.50
947.06
1,963.94
Non-Current Liabilities
965.72
1,264.45
813.65
2,342.88
2,067.29
2,048.67
2,760.03
285.79
306.42
900.59
Secured Loans
744.86
873.43
601.79
1,806.45
1,551.09
1,622.87
2,614.88
250.23
274.29
731.15
Unsecured Loans
90.77
9.15
2.12
0.06
0.23
14.84
12.13
17.16
1.24
0.00
Long Term Provisions
64.28
246.50
63.95
52.24
16.55
25.19
14.45
6.02
16.56
57.25
Current Liabilities
3,411.68
2,738.35
2,544.86
2,662.24
1,899.30
3,103.87
1,891.98
1,019.94
707.37
1,797.29
Trade Payables
1,071.52
1,134.20
797.75
888.99
712.07
774.09
775.40
234.41
262.31
463.08
Other Current Liabilities
697.18
421.00
354.49
248.12
129.98
819.08
347.93
502.47
127.27
651.65
Short Term Borrowings
1,496.53
1,023.84
1,228.78
1,339.02
944.39
1,393.96
700.48
203.03
224.56
599.89
Short Term Provisions
146.43
159.31
163.84
186.11
112.86
116.73
68.19
80.03
93.23
82.66
Total Liabilities
6,760.72
6,816.80
5,953.17
7,806.77
6,584.90
8,034.86
7,360.09
2,469.36
2,096.29
4,795.97
Net Block
2,333.45
2,151.13
2,025.85
3,570.13
2,903.00
2,909.03
2,678.68
701.36
554.53
3,016.72
Gross Block
3,231.69
2,841.28
2,534.38
4,049.05
3,229.03
3,186.12
2,825.43
1,080.55
907.33
3,514.29
Accumulated Depreciation
898.24
690.15
508.53
478.92
326.03
277.09
146.75
379.19
352.80
497.57
Non Current Assets
3,398.88
3,999.57
3,581.05
4,758.05
4,101.31
4,243.05
3,845.20
1,039.91
787.65
3,383.87
Capital Work in Progress
291.08
447.37
412.95
453.03
620.29
780.18
814.88
171.17
99.47
241.44
Non Current Investment
553.51
666.23
503.24
494.34
350.08
315.66
127.19
68.76
41.80
0.00
Long Term Loans & Adv.
208.50
185.80
210.82
223.69
197.22
222.56
201.83
96.72
90.40
118.75
Other Non Current Assets
12.34
549.04
428.19
16.86
30.72
15.62
22.62
1.91
1.45
6.96
Current Assets
3,361.83
2,817.23
2,372.11
3,048.72
2,483.59
3,791.82
3,514.89
1,429.44
1,308.63
1,410.94
Current Investments
0.00
99.41
118.97
284.75
311.48
1,279.54
1,213.76
561.29
401.24
0.06
Inventories
1,173.80
1,200.70
782.54
874.16
552.02
732.80
613.14
207.68
175.99
442.33
Sundry Debtors
1,207.30
1,110.59
931.69
987.18
882.18
995.91
1,032.97
389.96
364.00
483.23
Cash & Bank
187.35
179.76
237.10
516.65
303.33
329.48
311.59
146.88
231.15
165.74
Other Current Assets
793.39
98.22
83.57
136.87
434.59
454.09
343.44
123.64
136.26
319.58
Short Term Loans & Adv.
145.49
128.54
218.24
249.11
295.75
244.39
97.54
54.46
79.06
44.38
Net Current Assets
-49.84
78.89
-172.75
386.48
584.29
687.95
1,622.91
409.50
601.26
-386.35
Total Assets
6,760.71
6,816.80
5,953.16
7,806.77
6,584.90
8,034.87
7,360.09
2,469.35
2,096.28
4,795.98

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Cash From Operating Activity
-257.81
481.44
204.79
60.05
187.07
288.14
73.25
83.40
-271.68
134.26
PBT
-652.51
289.38
48.51
344.37
705.80
497.14
146.44
992.01
2,889.87
949.49
Adjustment
582.27
363.31
527.49
94.59
-274.51
190.92
345.56
-756.73
-2,775.01
-415.93
Changes in Working Capital
-189.90
-328.05
-326.23
-323.14
-190.66
-341.30
-341.71
-95.91
-260.68
-310.56
Cash after chg. in Working capital
-260.14
324.64
249.76
115.82
240.63
346.76
150.29
139.37
-145.81
223.00
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
2.33
156.80
-44.98
-55.76
-53.56
-58.62
-77.04
-55.97
-125.87
-88.75
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-118.73
-520.82
1,306.16
-148.49
582.59
-686.69
-2,224.83
51.87
4,077.09
806.54
Net Fixed Assets
-61.59
-86.75
-167.06
-48.49
677.20
-236.66
-535.93
-66.57
-119.10
-38.27
Net Investments
49.90
-219.57
-17.15
-383.09
747.64
-143.27
-1,478.58
78.09
248.81
-508.54
Others
-107.04
-214.50
1,490.37
283.09
-842.25
-306.76
-210.32
40.35
3,947.38
1,353.35
Cash from Financing Activity
421.32
-15.80
-1,709.45
194.27
-1,015.69
338.21
2,943.94
-421.25
-3,318.53
-990.03
Net Cash Inflow / Outflow
44.77
-55.18
-198.50
105.83
-246.03
-60.33
792.35
-285.98
486.88
-49.23
Opening Cash & Equivalents
125.83
182.23
365.89
256.16
515.08
1,110.74
298.91
586.00
132.02
211.93
Closing Cash & Equivalent
170.73
125.83
182.23
365.89
256.16
515.08
1,110.74
298.42
586.00
132.02

Financial Ratios

Consolidated /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Book Value (Rs.)
262.48
309.09
281.55
294.94
274.26
306.41
296.83
191.91
168.99
343.78
ROA
-5.35%
5.35%
2.00%
5.22%
9.59%
5.79%
2.03%
0.04%
1.48%
14.07%
ROE
-14.17%
12.91%
5.34%
14.74%
27.00%
16.53%
5.25%
0.09%
3.36%
42.16%
ROCE
-7.28%
11.17%
6.01%
8.65%
16.07%
10.75%
7.54%
10.92%
7.76%
21.08%
Fixed Asset Turnover
1.75
2.04
1.50
1.17
1.04
1.27
1.47
1.21
0.61
0.27
Receivable days
79.41
68.09
70.88
79.95
102.49
96.77
90.73
114.71
114.80
193.43
Inventory Days
81.35
66.13
61.20
61.00
70.11
64.20
52.34
58.37
83.78
174.61
Payable days
267.95
264.54
138.58
146.59
116.23
117.33
75.51
76.81
112.69
253.28
Cash Conversion Cycle
-107.20
-130.32
-6.50
-5.64
56.37
43.64
67.55
96.27
85.89
114.76
Total Debt/Equity
1.18
0.76
0.78
1.22
1.03
1.35
1.34
0.78
0.54
0.79
Interest Cover
-2.06
3.49
2.00
5.92
4.68
3.71
1.85
4.13
1.84
10.12

News Update:


  • Strides Pharma's arm receives EIR from USFDA for Drug Products facility in Bengaluru
    1st Sep 2022, 09:27 AM

    This outcome for the DP facility comes after the USFDA on-site PAI at Stelis flagship manufacturing facility for several product submissions by the partners to the agency

    Read More
  • Strides Pharma Science’s arm recalls 1,032 bottles of Prednisone tablets
    22nd Aug 2022, 09:38 AM

    As per the USFDA, the company is recalling the affected lot due to presence of foreign tablet

    Read More
  • Strides Pharma Science’s arm receives USFDA approval for Naproxen Sodium OTC Softgel Capsules
    18th Aug 2022, 15:17 PM

    The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Naproxen Sodium Capsules, 220 mg, of Bionpharma Inc

    Read More
  • USFDA completes inspection at Strides Pharma Science's Singapore facility
    9th Aug 2022, 12:40 PM

    The inspection was completed successfully with Zero 483 observations

    Read More
  • Strides Pharma's arm gets USFDA’s approval for Cyclosporine Softgel Capsules
    3rd Aug 2022, 14:30 PM

    Strides is the first Indian company to get approval for the product

    Read More
  • Strides Pharma Scien - Quarterly Results
    29th Jul 2022, 13:11 PM

    Read More
  • Strides Pharma Science gets nod to raise Rs 150 crore via NCDs
    26th Jul 2022, 09:09 AM

    The board of directors, at its meeting, held on July 25, 2022 has considered and approved the same

    Read More
  • Strides Pharma Science to raise funds through NCDs
    21st Jul 2022, 11:52 AM

    A meeting of the Committee of Directors is scheduled to be held on July 25, 2022, inter alia, to consider and approve the same

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.